References
- EichhornEJBristowMRMedical therapy can improve the biological properties of the chronic heart: A new era in the treatment of heart failureCirculation1996942285968901684
- JuurlinkDNMamdahiMMLosDSRates of hyperkalemia after publication of the Randomized Aldactone Evaluation StudyN Eng J Med200435254351
- McKelvieRSYusufSPericakDComparison of candesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The Resolved Pilot Study InvestigatorsCirculation199910010566410477530
- OverdichHJMerkusFWThe metabolism in biopharmaceuticals of spironolactone in manRev Drug Metab Drug Interact198752733023333882
- PittBRemmeWZannadFEplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med200334813092112668699
- PittBWhiteHNicolauJEplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failureJ Am Coll Cardiol2005464253116053953
- PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med19993417091710471456
- SwedbergKEnerothPKjekshusJHormones regulating cardiovascular function in Patients with Severe Congestive Heart Failure and their relation to mortality. Consensus Trial Study GroupCirculation199082173062225374
- WeintraubWSZhangZMahoneyEMCost effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failureCirculation200511111061315723981